Abstract:Key PointsThe dominant rationale to generate new (and to assess old) anticancer chemotherapeutic agents is to determine their cell-autonomous effects — that is, their capacity to reduce the growth (cytostasis) and to induce the death (cytotoxicity) of tumour cells in vitro and in vivo (usually in immunodeficient mice that have been xenotransplanted with human tumours). Experimental data obtained from immuncompetent mice and clinical data obtained from patients indicate that several chemotherapeutic agents have unexpected effects on the immune system. At least in some instances, these 'side effects' can contribute to the therapeutic effects of anticancer drugs.A non-exhaustive list of examples of drugs that combine anticancer and immunostimulatory effects includes: imatinib mesylate, cyclophosphamide, anthracyclines and 5-fluorouracil.Imatinib mesylate, a protein tyrosine kinase inhibitor, can induce caspase-independent death of tumour cells, can enhance natural killer (NK)-cell activities and can induce the expansion of a specific NK-cell subset that also bears dendritic-cell markers, known as interferon-producing killer dendritic cells, which in turn have tumoricidal effects.Cyclophosphamide, a DNA-alkylating agent, induces non-apoptotic cell death of tumour cells and T cells. In addition, it can deplete regulatory T cells, thereby overriding their antitumour immune responses.Anthracyclines can induce an immunogenic variant of apoptosis in tumour cells, thereby eliciting an antitumour immune response that is mediated by dendritic cells and cytotoxic T cells.5-Fluorouracil and other p53-activating cytotoxic drugs promote increased expression of tumour-associated antigens and co-stimulatory molecules on tumour cells.These agents illustrate the therapeutic feasibility of an 'immunogenic chemotherapy'; that is, a programme of chemotherapy that aims at stimulating the antitumour immune response as a warranted side effect of the therapy. Moreover, it might be possible to combine agents that induce direct cancer-cell-specific and immunostimulatory effects for an optimal therapeutic outcome.Theoretically, the induction of immunogenic cancer-cell death or other immunogenic effects should be one of the aims of anticancer chemotherapy so that the immune system can contribute through a 'bystander effect' to eradicate chemotherapy-resistant cancer cells and cancer stem cells.

Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia

Desirable Cell Death During Anticancer Chemotherapy

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment

Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells.

How to improve the immunogenicity of chemotherapy and radiotherapy

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review

Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions

Immunological aspects of cancer chemotherapy

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Deregulation of New Cell Death Mechanisms in Leukemia

Apoptosis, a Metabolic "Head-to-Head" between Tumor and T Cells: Implications for Immunotherapy

[Contributions of Immunogenic Cell Death to the Efficacy of Anticancer Chemotherapy].

The Effect of Chemotherapy on Programmed Cell Death 1/programmed Cell Death 1 Ligand Axis: Some Chemotherapeutical Drugs May Finally Work Through Immune Response

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Trial watch: chemotherapy-induced immunogenic cell death in oncology

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses

Cell death pathologies: targeting death pathways and the immune system for cancer therapy

Clinical Aspects and Significance of β-Chemokines, γ-Chemokines, and δ-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS)